• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Nolte Alexander

    5/22/23 5:00:27 PM ET
    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ONCR alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Nolte Alexander

    (Last) (First) (Middle)
    C/O ONCORUS, INC.
    4 CORPORATE DRIVE

    (Street)
    ANDOVER MA 01810

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/09/2023
    3. Issuer Name and Ticker or Trading Symbol
    Oncorus, Inc. [ ONCR ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CFO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Brian J. Shea, Attorney-in-Fact 05/22/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      8/7/23 6:52:07 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Oncorus Inc.

      15-12G - Oncorus, Inc. (0001671818) (Filer)

      8/3/23 5:00:26 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      7/28/23 4:40:36 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Appoints Douglas Fambrough to Board of Directors

      -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

      6/23/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

      CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

      5/10/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Shea Brian J. claimed ownership of 8,541 shares

      3 - Oncorus, Inc. (0001671818) (Issuer)

      6/16/23 9:20:42 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Nolte Alexander

      3 - Oncorus, Inc. (0001671818) (Issuer)

      5/22/23 5:00:27 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Flynn James E sold $88,254 worth of shares (336,235 units at $0.26)

      4 - Oncorus, Inc. (0001671818) (Issuer)

      12/30/22 7:16:31 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care